EFHD2

Across TCGA pan-cancer cohorts, EFHD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EFHD2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher EFHD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EFHD2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

COAD, CCRCC, and PDAC are the cancer types where EFHD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.914	1.000	.016	36	view →
CCRCC	OS	Quartile	II,III,IV	0.717	0.959	.020	7	view →
PDAC	OS	Quartile	II,III,IV	0.941	0.735	.005	5	view →
LUAD	OS	Quartile	II,III,IV	0.266	0.691	.010	2	view →
HNSC	DFS	Tertile	III,IV	0.911	1.000	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EFHD2–COAD (DFS)

Open the COAD breakdown →